| Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia (NCT02896829) | University Hospital, Bordeaux | 2013-04-03 |
| Nilotinib Plus Pegylated Interferon-α2b in CML (NCT01866553) | Amsterdam UMC, location VUmc | 2013-04-01 |
| Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy (NCT01819558) | Institut Paoli-Calmettes | 2013-03-01 |
| Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (NCT01802450) | PETHEMA Foundation | 2013-03-01 |
| Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) (NCT01698905) | Novartis Pharmaceuticals | 2012-12-20 |
| Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis (NCT01749111) | Hospital Israelita Albert Einstein | 2012-12-01 |
| Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body (NCT01795716) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2012-09-01 |
| TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (NCT01657604) | University of Jena | 2012-08-24 |
| Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies (NCT01606579) | Prism Pharma Co., Ltd. | 2012-07-01 |
| Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia (NCT01805843) | Medical University of Graz | 2012-07-01 |
| Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) (NCT01650805) | Ariad Pharmaceuticals | 2012-06-01 |
| European Stop Tyrosine Kinase Inhibitor Study (NCT01596114) | European LeukemiaNet | 2012-05-30 |
| A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) (NCT01751919) | Dong-A ST Co., Ltd. | 2012-05-01 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) (NCT01220648) | Novartis Pharmaceuticals | 2012-04-01 |
| Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial (NCT01627132) | Shimousa Hematology Study Group | 2012-02-01 |
| Nilotinib in PH+, BCR-, ABL+ CML Patients (NCT01535391) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2012-01-01 |
| Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients (NCT01578213) | University of Milano Bicocca | 2011-11-09 |
| Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib (NCT01562847) | Seoul St. Mary's Hospital | 2011-07-01 |
| Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients (NCT01169753) | M.D. Anderson Cancer Center | 2011-05-01 |
| Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML) (NCT01394666) | Bristol-Myers Squibb | 2011-05-01 |
| Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients (NCT01275196) | Novartis Pharmaceuticals | 2011-04-01 |
| Phase I Study of OPB-51602 in Patients With Hematologic Malignancies (NCT01344876) | Otsuka Pharmaceutical Co., Ltd. | 2011-04-01 |
| A Study of Complete Molecular Response for Chronic Myeloid Leukemia in Chronic Phase Patients, Treated With Dasatinib (NCT01342679) | Kanto CML Study Group | 2011-04-01 |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (NCT01254188) | Novartis Pharmaceuticals | 2011-04-01 |
| Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia (NCT01297543) | Cellerant Therapeutics | 2011-03-01 |
| International Chronic Myeloid Leukemia Pediatric Study (NCT01281735) | Poitiers University Hospital | 2011-01-01 |
| Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (NCT01244750) | Bristol-Myers Squibb | 2010-12-02 |
| Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza (NCT01290302) | American Regent, Inc. | 2010-11-22 |
| Patient Reported Outcomes in Chronic Myeloid Leukemia (NCT01252589) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2010-11-01 |
| Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects (NCT01270984) | Chong Kun Dang Pharmaceutical | 2010-11-01 |
| A Study Investigating the Predictive Value of Philadelphia Positive Stem Cell Properties in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase Receiving Treatment With Imatinib (NCT01215487) | University of British Columbia | 2010-10-01 |
| Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (NCT01207440) | Ariad Pharmaceuticals | 2010-09-30 |
| Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (NCT01167166) | Traws Pharma, Inc. | 2010-07-01 |
| Discontinuation Study of Imatinib in Adult CP CML Patients Who Have a Complete Molecular Response to Imatinib (NCT01564836) | Seoul St. Mary's Hospital | 2010-06-01 |
| To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib (NCT01223898) | Novartis Pharmaceuticals | 2010-06-01 |
| A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation (NCT01068301) | St. Jude Children's Research Hospital | 2010-05-01 |
| Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line Therapy (NCT00896129) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2010-03-01 |
| Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia (NCT00895297) | European Society for Blood and Marrow Transplantation | 2010-02-01 |
| Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma (NCT00965224) | Zwi Berneman | 2010-01-01 |
| Follow-up of Ph+ Chronic Myleoid Leukemia Patients in Complete Cytogenetic Response With Interferon Based Therapy (NCT01490853) | Università degli Studi di Brescia | 2009-10-01 |
| Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (NCT00988013) | University of Illinois at Chicago | 2009-09-01 |
| T-cell Depleted Alternative Donor Transplantation (NCT00968864) | Wake Forest University Health Sciences | 2009-08-01 |
| Investigating Intracellular and Plasma Imatinib Levels in Chronic Myeloid Leukemia (NCT00947830) | Brian Leber | 2009-07-01 |
| Nilotinib Pre and Post Allogeneic Stem Cell Transplantation (NCT00750659) | Sheba Medical Center | 2009-07-01 |
| Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha (NCT01073436) | University of Michigan Rogel Cancer Center | 2009-05-01 |
| Allogeneic Stem Cell Transplantation for Children With CML (NCT02707393) | St. Anna Kinderkrebsforschung | 2009-04-30 |
| Telemonitoring Study - for Chronic Myeloid Leukemia (CML) (NCT01490983) | Rex Cancer Center, Raleigh, NC | 2009-04-01 |
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (NCT00852566) | Norwegian University of Science and Technology | 2009-03-01 |
| A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia (NCT00866736) | Kanto CML Study Group | 2009-03-01 |
| Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) (NCT00827138) | Deciphera Pharmaceuticals, LLC | 2009-03-01 |
| Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib (NCT01400074) | Seoul St. Mary's Hospital | 2009-01-01 |
| CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene (NCT00710892) | Baylor College of Medicine | 2008-12-01 |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy (NCT00815321) | Singapore General Hospital | 2008-12-01 |
| Bendamustine in Acute Leukemia and MDS (NCT00790855) | M.D. Anderson Cancer Center | 2008-11-01 |
| Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility (NCT01114087) | Assistance Publique - Hôpitaux de Paris | 2008-10-01 |
| Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (NCT00905593) | Novartis Pharmaceuticals | 2008-09-01 |
| Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (NCT00786812) | Novartis Pharmaceuticals | 2008-08-01 |
| Palifermin After Haploidentical PBSCT (NCT00570999) | European Society for Blood and Marrow Transplantation | 2008-02-01 |
| Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment (NCT00632255) | Imperial College London | 2008-01-01 |
| Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia (NCT00573378) | University of Michigan Rogel Cancer Center | 2007-09-01 |
| Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies (NCT00593554) | Sherif S. Farag | 2007-08-07 |
| Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT (NCT01683123) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2007-07-01 |
| Nilotinib as First-line Treatment of Ph+ CML in Early Chronic Phase (NCT00481052) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2007-06-23 |
| Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (NCT00464113) | Exelixis | 2007-05-01 |
| Natural Killer Index From Hematopoietic Stem Cell Graft (NCT00435864) | Nantes University Hospital | 2007-04-01 |
| Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML (NCT00462943) | Teva Branded Pharmaceutical Products R&D, Inc. | 2007-03-07 |
| Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia (NCT00162513) | Hadassah Medical Organization | 2006-12-01 |
| Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL (NCT00349518) | Bristol-Myers Squibb | 2006-12-01 |
| Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation (NCT00375219) | Teva Branded Pharmaceutical Products R&D, Inc. | 2006-09-20 |
| Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias (NCT00522990) | Astex Pharmaceuticals, Inc. | 2006-09-01 |
| Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies (NCT00460694) | Singapore General Hospital | 2006-08-01 |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia (NCT00352677) | CytRx | 2006-07-01 |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias (NCT00261846) | Pfizer | 2006-01-18 |
| Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia (NCT00302016) | Novartis Pharmaceuticals | 2006-01-01 |
| Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease (NCT00267085) | M.D. Anderson Cancer Center | 2005-12-01 |
| Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation (NCT00328237) | Colorado Blood Cancer Institute | 2005-11-01 |
| Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients (NCT00493181) | M.D. Anderson Cancer Center | 2005-10-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (NCT00598624) | IRCCS San Raffaele | 2005-09-01 |
| Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) (NCT00257647) | Hadassah Medical Organization | 2005-09-01 |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies (NCT00143559) | St. Jude Children's Research Hospital | 2005-08-01 |
| Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant (NCT00354120) | Gruppo Italiano Trapianto di Midollo Osseo | 2005-03-01 |
| Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation (NCT00460629) | University Hospital Carl Gustav Carus | 2005-03-01 |
| Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to Imatinib (NCT00101660) | Bristol-Myers Squibb | 2005-02-01 |
| Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia (NCT00103844) | Bristol-Myers Squibb | 2005-02-01 |
| Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (NCT00101595) | Bristol-Myers Squibb | 2005-01-01 |
| Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate (NCT00101816) | Bristol-Myers Squibb | 2004-12-01 |
| Glivec in Pediatric Chronic Myeloid Leukemia (CML) (NCT00845221) | Poitiers University Hospital | 2004-07-01 |
| Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) (NCT00514488) | University of Bologna | 2004-06-01 |
| HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (NCT00145626) | St. Jude Children's Research Hospital | 2004-05-01 |
| AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year (NCT00146913) | Hospices Civils de Lyon | 2004-03-01 |
| Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (NCT00327262) | Central European Leukemia Study Group | 2004-01-01 |
| Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) (NCT00067028) | M.D. Anderson Cancer Center | 2003-12-01 |
| STI571 ProspectIve RandomIzed Trial: SPIRIT (NCT00219739) | Poitiers University Hospital | 2003-09-01 |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies (NCT00145613) | St. Jude Children's Research Hospital | 2003-06-01 |
| Reduced Intensity AlloSCT in(CML) With Persistent Disease (NCT00531310) | Columbia University | 2003-01-01 |
| Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT (NCT00516152) | University of California, San Francisco | 2002-11-01 |
| Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 Years (NCT00219752) | Poitiers University Hospital | 2002-05-01 |
| Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation (NCT00219726) | Poitiers University Hospital | 2002-05-01 |
| Stem Cell Transplantation for Patients With Hematologic Malignancies (NCT00152139) | St. Jude Children's Research Hospital | 2002-05-01 |